항고혈압제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2022-2031년)

Antihypertensive Drugs Market - Scope of Report

TMR's report on the global antihypertensive drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global antihypertensive drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global antihypertensive drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the antihypertensive drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global antihypertensive drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global antihypertensive drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global antihypertensive drugs market.

The report delves into the competitive landscape of the global antihypertensive drugs market. Key players operating in the global antihypertensive drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global antihypertensive drugs market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market antihypertensive drugs.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants' insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

• Company websites, presentations, annual reports, white papers, technical paper, product brochure
• Internal and external proprietary databases and relevant patents
• National government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:

• WorldWideScience.org
• Elsevier, Inc.
• National Institutes of Health (NIH)
• PubMed
• NCBI
• Department of Health Care Service
• Trade Data Sources
• Trade Map
• UN Comtrade
• Trade Atlas
• Company Information
• OneSource Business Browser
• Hoover's
• Factiva
• Bloomberg
• Mergers & Acquisitions
• Thomson Mergers & Acquisitions
• MergerStat
• Profound
• Primary Research
• During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

• Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
• Helps in validating and strengthening secondary research findings
• Further develops the analysis team's expertise and market understanding
• Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

• Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
• Purchasing/Sourcing managers, technical personnel, distributors
• Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
• Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

• Advanced Oncotherapy PLC
• Danfysik A/S
• Hitachi, Ltd.
• IBA Worldwide
• Mevion Medical Systems, Inc.
• Data Triangulation: Information culled from "Secondary & Primary Sources" is cross-checked with "TMR Knowledge Repository", which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

• Demographic Data: Healthcare expenditure, inflation rates, and others
• Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
• Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antihypertensive Drugs Market

4. Market Overview

• 4.1. Introduction
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Market Outlook

• 5.1. Key Industry Developments
• 5.2. Impact scenario
• 5.3. New product developments

6. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type

• 6.1. Introduction & Definition
• 6.2. Global Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
  • 6.2.1. Diuretics
    • 6.2.1.1. Thiazide diuretics
    • 6.2.1.2. Loop diuretics
    • 6.2.1.3. Potassium-sparing diuretics
  • 6.2.2. Angiotensin Converting Enzyme Inhibitors
  • 6.2.3. Angiotensin Receptor Blockers
  • 6.2.4. Beta-blockers
    • 6.2.4.1. Beta-1 Selective
    • 6.2.4.2. Intrinsic Sympathomimetic
  • 6.2.5. Vasodilators
  • 6.2.6. Calcium Channel Blockers
  • 6.2.7. Renin Inhibitors
  • 6.2.8. Alpha-blockers
  • 6.2.9. Others
• 6.3. Global Antihypertensive Drugs Market Attractiveness, by Therapy Type

7. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type

• 7.1. Introduction & Definition
• 7.2. Global Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
  • 7.2.1. Primary Hypertension
  • 7.2.2. Secondary Hypertension
• 7.3. Global Antihypertensive Drugs Market Attractiveness, by Type

8. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type

• 8.1. Introduction
• 8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
  • 8.2.1. Monotherapy
  • 8.2.2. Combination Therapy
  • 8.2.3. Fixed Dose Combinations
• 8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type

9. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel

• 9.1. Introduction
• 9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
  • 9.2.1. Retail Pharmacies
  • 9.2.2. Hospital Pharmacies
  • 9.2.3. Online Pharmacies
  • 9.2.4. Others
• 9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel

10. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Region

• 10.1. Introduction
• 10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017-2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Global Antihypertensive Drugs Market Attractiveness, by Region

11. North America Antihypertensive Drugs Market Analysis and Forecast

• 11.1. Introduction
• 11.2. North America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
  • 11.2.1. Diuretics
    • 11.2.1.1. Thiazide diuretics
    • 11.2.1.2. Loop diuretics
    • 11.2.1.3. Potassium-sparing diuretics
  • 11.2.2. Angiotensin Converting Enzyme Inhibitors
  • 11.2.3. Angiotensin Receptor Blockers
  • 11.2.4. Beta-blockers
    • 11.2.4.1. Beta-1 Selective
    • 11.2.4.2. Intrinsic Sympathomimetic
  • 11.2.5. Vasodilators
  • 11.2.6. Calcium Channel Blockers
  • 11.2.7. Renin Inhibitors
  • 11.2.8. Alpha-blockers
  • 11.2.9. Others
• 11.3. North America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
  • 11.3.1. Primary Hypertension
  • 11.3.2. Secondary Hypertension
• 11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
  • 11.4.1. Monotherapy
  • 11.4.2. Combination Therapy
  • 11.4.3. Fixed Dose Combinations
  • 11.4.4. Others
• 11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.5.1. Retail Pharmacies
  • 11.5.2. Hospital Pharmacies
  • 11.5.3. Online Pharmacies
  • 11.5.4. Others
• 11.6. North America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. North America Antihypertensive Drugs Market Attractiveness Analysis
  • 11.7.1. By Therapy Type
  • 11.7.2. By Type
  • 11.7.3. By Medication Type
  • 11.7.4. By Distribution Channel
  • 11.7.5. By Country/Sub-region

12. Europe Antihypertensive Drugs Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Europe Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
  • 12.2.1. Diuretics
    • 12.2.1.1. Thiazide diuretics
    • 12.2.1.2. Loop diuretics
    • 12.2.1.3. Potassium-sparing diuretics
  • 12.2.2. Angiotensin Converting Enzyme Inhibitors
  • 12.2.3. Angiotensin Receptor Blockers
  • 12.2.4. Beta-blockers
    • 12.2.4.1. Beta-1 Selective
    • 12.2.4.2. Intrinsic Sympathomimetic
  • 12.2.5. Vasodilators
  • 12.2.6. Calcium Channel Blockers
  • 12.2.7. Renin Inhibitors
  • 12.2.8. Alpha-blockers
  • 12.2.9. Others
• 12.3. Europe Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
  • 12.3.1. Primary Hypertension
  • 12.3.2. Secondary Hypertension
• 12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
  • 12.4.1. Monotherapy
  • 12.4.2. Combination Therapy
  • 12.4.3. Fixed Dose Combinations
  • 12.4.4. Others
• 12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.5.1. Retail Pharmacies
  • 12.5.2. Hospital Pharmacies
  • 12.5.3. Online Pharmacies
  • 12.5.4. Others
• 12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Spain
  • 12.6.5. Italy
  • 12.6.6. Rest of Europe
• 12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis
  • 12.7.1. By Therapy Type
  • 12.7.2. By Type
  • 12.7.3. By Medication Type
  • 12.7.4. By Distribution Channel
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
  • 13.2.1. Diuretics
    • 13.2.1.1. Thiazide diuretics
    • 13.2.1.2. Loop diuretics
    • 13.2.1.3. Potassium-sparing diuretics
  • 13.2.2. Angiotensin Converting Enzyme Inhibitors
  • 13.2.3. Angiotensin Receptor Blockers
  • 13.2.4. Beta-blockers
    • 13.2.4.1. Beta-1 Selective
    • 13.2.4.2. Intrinsic Sympathomimetic
  • 13.2.5. Vasodilators
  • 13.2.6. Calcium Channel Blockers
  • 13.2.7. Renin Inhibitors
  • 13.2.8. Alpha-blockers
  • 13.2.9. Others
• 13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
  • 13.3.1. Primary Hypertension
  • 13.3.2. Secondary Hypertension
• 13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
  • 13.4.1. Monotherapy
  • 13.4.2. Combination Therapy
  • 13.4.3. Fixed Dose Combinations
  • 13.4.4. Others
• 13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.5.1. Retail Pharmacies
  • 13.5.2. Hospital Pharmacies
  • 13.5.3. Online Pharmacies
  • 13.5.4. Others
• 13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. Japan
  • 13.6.2. China
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis
  • 13.7.1. By Therapy Type
  • 13.7.2. By Type
  • 13.7.3. By Medication Type
  • 13.7.4. By Distribution Channel
  • 13.7.5. By Country/Sub-region

14. Latin America Antihypertensive Drugs Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
  • 14.2.1. Diuretics
    • 14.2.1.1. Thiazide diuretics
    • 14.2.1.2. Loop diuretics
    • 14.2.1.3. Potassium-sparing diuretics
  • 14.2.2. Angiotensin Converting Enzyme Inhibitors
  • 14.2.3. Angiotensin Receptor Blockers
  • 14.2.4. Beta-blockers
    • 14.2.4.1. Beta-1 Selective
    • 14.2.4.2. Intrinsic Sympathomimetic
  • 14.2.5. Vasodilators
  • 14.2.6. Calcium Channel Blockers
  • 14.2.7. Renin Inhibitors
  • 14.2.8. Alpha-blockers
  • 14.2.9. Others
• 14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
  • 14.3.1. Primary Hypertension
  • 14.3.2. Secondary Hypertension
• 14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
  • 14.4.1. Monotherapy
  • 14.4.2. Combination Therapy
    • 14.4.2.1. Thiazide diuretics
    • 14.4.2.2. Loop diuretics
    • 14.4.2.3. Potassium-sparing diuretics
  • 14.4.3. Angiotensin Converting Enzyme Inhibitors
  • 14.4.4. Angiotensin Receptor Blockers
  • 14.4.5. Beta-blockers
    • 14.4.5.1. Beta-1 Selective
    • 14.4.5.2. Intrinsic Sympathomimetic
  • 14.4.6. Vasodilators
  • 14.4.7. Calcium Channel Blockers
  • 14.4.8. Renin Inhibitors
  • 14.4.9. Alpha-blockers
  • 14.4.10. Others
• 14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
  • 14.5.1. Primary Hypertension
  • 14.5.2. Secondary Hypertension
• 14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
  • 14.6.1. Monotherapy
  • 14.6.2. Combination Therapy
  • 14.6.3. Fixed Dose Combinations
  • 14.6.4. Others
• 14.7. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.7.1. Retail Pharmacies
  • 14.7.2. Hospital Pharmacies
  • 14.7.3. Online Pharmacies
  • 14.7.4. Others
• 14.8. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.8.1. Brazil
  • 14.8.2. Mexico
  • 14.8.3. Rest of Latin America
• 14.9. Latin America Antihypertensive Drugs Market Attractiveness Analysis
  • 14.9.1. By Therapy Type
  • 14.9.2. By Type
  • 14.9.3. By Medication Type
  • 14.9.4. By Distribution Channel
  • 14.9.5. By Country/Sub-region

15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast

• 15.1. Introduction
• 15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
  • 15.2.1. Diuretics
    • 15.2.1.1. Thiazide diuretics
    • 15.2.1.2. Loop diuretics
    • 15.2.1.3. Potassium-sparing diuretics
  • 15.2.2. Angiotensin Converting Enzyme Inhibitors
  • 15.2.3. Angiotensin Receptor Blockers
  • 15.2.4. Beta-blockers
    • 15.2.4.1. Beta-1 Selective
    • 15.2.4.2. Intrinsic Sympathomimetic
  • 15.2.5. Vasodilators
  • 15.2.6. Calcium Channel Blockers
  • 15.2.7. Renin Inhibitors
  • 15.2.8. Alpha-blockers
  • 15.2.9. Others
• 15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
  • 15.3.1. Primary Hypertension
  • 15.3.2. Secondary Hypertension
• 15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
  • 15.4.1. Monotherapy
  • 15.4.2. Combination Therapy
  • 15.4.3. Fixed Dose Combinations
  • 15.4.4. Others
• 15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
  • 15.5.1. Retail Pharmacies
  • 15.5.2. Hospital Pharmacies
  • 15.5.3. Online Pharmacies
  • 15.5.4. Others
• 15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Israel
  • 15.6.4. Rest of Middle East & Africa
• 15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis
  • 15.7.1. By Therapy Type
  • 15.7.2. By Type
  • 15.7.3. By Medication Type
  • 15.7.4. By Distribution Channel
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (by tier and size of companies)
• 16.2. Company Profiles
  • 16.2.1. Pfizer, Inc.
    • 16.2.1.1. Company Description
    • 16.2.1.2. Business Overview
    • 16.2.1.3. Financial Overview
    • 16.2.1.4. Strategic Overview
    • 16.2.1.5. SWOT Analysis
  • 16.2.2. Sanofi S.A
    • 16.2.2.1. Company Description
    • 16.2.2.2. Business Overview
    • 16.2.2.3. Financial Overview
    • 16.2.2.4. Strategic Overview
    • 16.2.2.5. SWOT Analysis
  • 16.2.3. Novartis AG
    • 16.2.3.1. Company Description
    • 16.2.3.2. Business Overview
    • 16.2.3.3. Financial Overview
    • 16.2.3.4. Strategic Overview
    • 16.2.3.5. SWOT Analysis
  • 16.2.4. Boehringer Ingelheim GmbH
    • 16.2.4.1. Company Description
    • 16.2.4.2. Business Overview
    • 16.2.4.3. Financial Overview
    • 16.2.4.4. Strategic Overview
    • 16.2.4.5. SWOT Analysis
  • 16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)
    • 16.2.5.1. Company Description
    • 16.2.5.2. Business Overview
    • 16.2.5.3. Financial Overview
    • 16.2.5.4. Strategic Overview
    • 16.2.5.5. SWOT Analysis
  • 16.2.6. F. Hoffmann-La Roche Ltd.
    • 16.2.6.1. Company Description
    • 16.2.6.2. Business Overview
    • 16.2.6.3. Financial Overview
    • 16.2.6.4. Strategic Overview
    • 16.2.6.5. SWOT Analysis
  • 16.2.7. Bayer AG
    • 16.2.7.1. Company Description
    • 16.2.7.2. Business Overview
    • 16.2.7.3. Financial Overview
    • 16.2.7.4. Strategic Overview
    • 16.2.7.5. SWOT Analysis
  • 16.2.8. Daiichi Sankyo Company, Limited
    • 16.2.8.1. Company Description
    • 16.2.8.2. Business Overview
    • 16.2.8.3. Financial Overview
    • 16.2.8.4. Strategic Overview
    • 16.2.8.5. SWOT Analysis
  • 16.2.9. Takeda Pharmaceutical Company Limited
    • 16.2.9.1. Company Description
    • 16.2.9.2. Business Overview
    • 16.2.9.3. Financial Overview
    • 16.2.9.4. Strategic Overview
    • 16.2.9.5. SWOT Analysis